

Charu Aggarwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3919231/publications.pdf>

Version: 2024-02-01

78
papers

4,011
citations

218677

26
h-index

128289

60
g-index

78
all docs

78
docs citations

78
times ranked

6371
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. <i>JCO Oncology Practice</i> , 2022, 18, e426-e441.	2.9	16
2	Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy. <i>Clinical Lung Cancer</i> , 2022, 23, e301-e309.	2.6	2
3	Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed. <i>Clinical Lung Cancer</i> , 2022, 23, e310-e316.	2.6	1
4	A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers. <i>Oral Oncology</i> , 2022, 127, 105798.	1.5	8
5	Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100301.	1.1	7
6	COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3383-3393.	1.6	120
7	Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3103-3105.	1.6	3
8	Adjuvant Osimertinib: A New Standard of Care. <i>Oncologist</i> , 2021, 26, 263-265.	3.7	5
9	Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. <i>Clinical Lung Cancer</i> , 2021, 22, 58-66.e3.	2.6	19
10	Integration of Risk Survival Measures Estimated From Pre- and Posttreatment Computed Tomography Scans Improves Stratification of Patients With Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1647-1656.	0.8	9
11	Increased rate of recurrence and high rate of salvage in patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma with adverse features treated with primary surgery without recommended adjuvant therapy. <i>Head and Neck</i> , 2021, 43, 1128-1141.	2.0	17
12	Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 56-62.	27.6	99
13	Abstract P17: Effect of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic. , 2021, , .		0
14	Plasma Tumor Mutation Burden and Response to Pembrolizumab—Response. <i>Clinical Cancer Research</i> , 2021, 27, 1581-1581.	7.0	2
15	Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 510-524.	3.0	36
16	Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors. <i>Scientific Reports</i> , 2021, 11, 9984.	3.3	13
17	Survival and toxicity in patients with human papilloma virus-associated oropharyngeal squamous cell cancer receiving trimodality therapy including transoral robotic surgery. <i>Head and Neck</i> , 2021, 43, 3053-3061.	2.0	2
18	Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 937.	7.1	48

#	ARTICLE	IF	CITATIONS
19	Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery. <i>Oral Oncology</i> , 2021, 118, 105307.	1.5	21
20	Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2021, 26, e1812-e1821.	3.7	15
21	Optimization of Sources of Circulating Cell-Free DNA Variability for Downstream Molecular Analysis. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1545-1552.	2.8	4
22	Multiblock Discriminant Analysis of Integrative 18F-FDG-PET/CT Radiomics for Predicting Circulating Tumor Cells in Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1451-1465.	0.8	9
23	Molecular testing in stage III non-small cell lung cancer: Approaches and challenges. <i>Lung Cancer</i> , 2021, 162, 42-53.	2.0	22
24	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	1.1	274
25	Immunotherapy for Head and Neck Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1021-1037.	2.2	8
26	Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic. <i>BMC Cancer</i> , 2021, 21, 1094.	2.6	7
27	Impact of Interobserver Variability in Manual Segmentation of Non-Small Cell Lung Cancer (NSCLC) Applying Low-Rank Radiomic Representation on Computed Tomography. <i>Cancers</i> , 2021, 13, 5985.	3.7	7
28	KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (NSCLC). , 2021, 9, A485-A485.		5
29	A Phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed After Transoral Robotic Surgery for Human Papilloma Virus-Related Squamous Cell Carcinoma of the Oropharynx. <i>International Journal of Radiation Oncology Biology Physics</i> . 2020, 106, 725-732.	0.8	103
30	Oncologic Outcomes Following Transoral Robotic Surgery for Human Papillomavirus-Associated Oropharyngeal Carcinoma in Older Patients. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 1167.	2.2	2
31	Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. <i>Cancer Medicine</i> , 2020, 9, 7511-7523.	2.8	8
32	A LIBRETTO to orchestrate targeted therapy. <i>Nature Cancer</i> , 2020, 1, 1038-1040.	13.2	1
33	Reply to A. Greenberg et al. <i>JCO Oncology Practice</i> , 2020, 16, 617-618.	2.9	0
34	Management of Lung Cancer During the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2020, 16, 579-586.	2.9	52
35	Plasma Tumor Mutation Burden and Response to Pembrolizumab Response. <i>Clinical Cancer Research</i> , 2020, 26, 3492-3492.	7.0	2
36	<sc>Penn</sc> Medicine Head and Neck Cancer Service Line <sc>COVID</sc>-19 management guidelines. <i>Head and Neck</i> , 2020, 42, 1507-1515.	2.0	9

#	ARTICLE	IF	CITATIONS
37	Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2354-2361.	7.0	70
38	Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 848.	7.1	89
39	Systemic therapy for elderly patients with nonâ€“small cell lung cancer: Where do we stand in 2019?. <i>Cancer</i> , 2020, 126, 931-934.	4.1	5
40	Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. <i>Vaccines</i> , 2020, 8, 56.	4.4	16
41	Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with <i>EGFR</i> exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9580-9580.	1.6	20
42	Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 87-97.	2.6	59
43	The impact of treatment package time on locoregional control for HPV+ oropharyngeal squamous cell carcinoma treated with surgery and postoperative (chemo)radiation. <i>Head and Neck</i> , 2019, 41, 3858-3868.	2.0	7
44	Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1513-1527.	1.1	83
45	Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1283.	7.1	220
46	Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancer. <i>British Journal of Radiology</i> , 2019, 92, 20190466.	2.2	3
47	Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer. <i>BMC Cancer</i> , 2019, 19, 603.	2.6	29
48	Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 222-229.	1.6	133
49	Immune Checkpoint Inhibitorâ€“Related Cardiovascular Toxicity in Lung Cancer. <i>JACC: CardioOncology</i> , 2019, 1, 193-195.	4.0	1
50	Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. <i>Journal of the National Cancer Institute</i> , 2019, 111, 490-497.	6.3	69
51	Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data. <i>Cancer</i> , 2019, 125, 406-415.	4.1	26
52	Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 173.	7.1	334
53	Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 110-124.	7.0	102
54	Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy. <i>Current Problems in Diagnostic Radiology</i> , 2019, 48, 142-147.	1.4	12

#	ARTICLE	IF	CITATIONS
55	Immunotherapy for head and neck cancer: where are we now and where are we going?. <i>Annals of Translational Medicine</i> , 2019, 7, S75-S75.	1.7	35
56	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1464-1472.	4.9	556
57	Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. <i>Molecular Therapy</i> , 2018, 26, 1198-1205.	8.2	24
58	Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study. <i>Clinical Lung Cancer</i> , 2018, 19, 157-162.	2.6	14
59	Molecular Characterization of Malignant Mesothelioma: Time for New Targets?. <i>Cancer Discovery</i> , 2018, 8, 1508-1510.	9.4	6
60	Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 978-986.	1.1	87
61	Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2017, 106, 1-7.	2.0	403
62	Unsupervised exercise in survivors of human papillomavirus related head and neck cancer: how many can go it alone?. <i>Journal of Cancer Survivorship</i> , 2017, 11, 462-468.	2.9	10
63	Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. <i>Oncologist</i> , 2017, 22, 700-708.	3.7	11
64	Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy. <i>Lung Cancer</i> , 2017, 112, 118-125.	2.0	48
65	Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e143-e149.	2.6	3
66	Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging. <i>Oncotarget</i> , 2017, 8, 24213-24223.	1.8	7
67	Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2017, 5, 380-380.	1.7	12
68	Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2016, 22, 5772-5782.	7.0	279
69	DNA-based immunotherapy for HPV-associated head and neck cancer. <i>Immunotherapy</i> , 2016, 8, 1187-1192.	2.0	5
70	Imaging for the Pretreatment Staging of Small cell Lung Cancer. <i>Academic Radiology</i> , 2016, 23, 1047-1056.	2.5	15
71	Immunotherapy for head and neck cancer: latest developments and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 168-175.	3.2	18
72	Investigational NEDD8-activating enzyme inhibitor pevonedistat (Pev) plus chemotherapy in patients (Pts) with solid tumors (Phase 1b study): Antitumor activity of pev plus carboplatin (Carbo)/paclitaxel (Pac).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2580-2580.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy. <i>Oncotarget</i> , 2015, 6, 30287-30294.	1.8	24
74	Multidisciplinary Therapy of Stage IIIA Non-Small-Cell Lung Cancer: Long-term Outcome of Chemoradiation with or without Surgery. <i>Cancer Control</i> , 2014, 21, 57-62.	1.8	24
75	Targeted therapy for lung cancer: present and future. <i>Annals of Palliative Medicine</i> , 2014, 3, 229-35.	1.2	32
76	Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist?. <i>Lung Cancer</i> , 2013, 81, 347-353.	2.0	81
77	Older age, poor performance status and major comorbidities. <i>Current Opinion in Oncology</i> , 2012, 24, 130-136.	2.4	18
78	Antiangiogenic agents in the management of non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2012, 13, 247-263.	3.4	63